α1肾上腺素能受体阻滞剂治疗Ⅲ型前列腺炎的临床观察

Clinical Observation of α1 Adrenergic Receptor Blocker in Treatment of Type Ⅲ Prostatitis

目的探讨α1肾上腺素能受体阻滞剂治疗Ⅲ型前列腺炎(CPPS/CAP)的疗效,探讨其治疗机制。方法选取我院CPPS/CAP患者110例,随机分为对照组与观察组。对照组予以左旋氧氟沙星,观察组在对照组基础上加用甲磺酸多沙唑嗪控释片。采用NIH-CPS Ⅰ评分作为疗效指标,对前列腺按摩液(EPS)及尿流动力学指标的变化进行检查。结果经治疗观察组排尿症状评分和总评分均显著低于对照组(P<0.05);MFR、AFR均有所提高(P<0.05),且显著高于对照组;MUP及MUCP均较治疗前明显降低(P<0.05),且优于对照组;观察组白细胞显著低于对照组(P<0.05)。观察组总有效率63.64%显著高于对照组41.82%(P<0.05)。结果α1肾上腺素能受体阻滞剂(甲磺酸多沙唑嗪控释片)治疗Ⅲ型前列腺炎可有效降低尿道压力,缓解前列腺内尿液返流,改善排尿障碍,提高治疗有效率,可作为治疗CPPS/CAP的基础用药。

Objective To investigate the curative effect and the therapeutic mechanism of α 1 adrenergic receptor blocker in treatment of type III prostatitis （CPPS/CAP）.Methods 110 cases of CPPS/CAP patients from the First People＆#39;＆#39;s Hospital of Longchang in Neijiang were randomly divided into the observation group and the control group.The control group were given Levofloxacin.And the observation group were given both Levofloxacin and Doxazosin Mesylate.The score of NIH-CPS I was used to analyse expressed prostatic secretion （EPS） and the changes of urodynamics index.Results With NIH-CPS I analyses after treatment, the scores of urination symptom and the total score in the observation group were significantly lower than those in the control group （P〈0.05, repectively）.MFR and AFR after treatment in the observation group were both significantly higher than those in the control group （P〈0.05）.And MUP and MUCP after treatment in the observation group were both significantly lower than those in the control group （P〈0.05）.Meanwhile, white blood cells in the observation group were significantly lower than that in the control group after treatment （P〈0.05）.The total effective rate in the observation group （63.64%） was significantly larger than that in the control group （41.82%） （P〈0.05）.Conclusion α 1 receptor blocker （Doxazosin Mesylate Controlled Release Tablets） can reduce urethral pressure effectively during the treatment of type III prostatitis.It can relieve the reflux of urine in the prostate, improve urination disorders, raise therapeutical effective rate and be the basis for the treatment of CPPS/CAP.